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Abstract: 41 
RBM15, an RNA binding protein, determines cell-fate specification of many tissues including blood. We 42 
demonstrate that RBM15 is methylated by protein arginine methyltransferase 1 (PRMT1) at residue 43 
R578 leading to its degradation via ubiquitylation by an E3 ligase (CNOT4). Overexpression of PRMT1 in 44 
acute megakaryocytic leukemia cell lines blocks megakaryocyte terminal differentiation by 45 
downregulation of RBM15 protein level. Restoring RBM15 protein level rescues megakaryocyte terminal 46 
differentiation blocked by PRMT1 overexpression. At the molecular level, RBM15 binds to pre-mRNA 47 
intronic regions of genes important for megakaryopoiesis such as GATA1, RUNX1, TAL1 and c-MPL. 48 
Furthermore, preferential binding of RBM15 to specific intronic regions recruits the splicing factor SF3B1 49 
to the same sites for alternative splicing. Therefore, PRMT1 regulates alternative RNA splicing via 50 
reducing RBM15 protein concentration. Targeting PRMT1 may be a curative therapy to restore 51 
megakaryocyte differentiation for acute megakaryocytic leukemia.    52 
3 
Introduction:  53 
RNA binding proteins control post-transcriptional processing such as alternative RNA splicing, 54 
polyadenylation and protein translation, which is a prevalent part of gene regulation in normal cell 55 
differentiation and in cancer development (Cabezas-Wallscheid et al., 2014; Chen et al., 2014; de Klerk 56 
and t Hoen, 2015; Shapiro et al., 2011). Arginine methylation of RNA binding proteins by protein arginine 57 
methyltransferases (PRMTs) regulates RNA splicing (Bedford and Clarke, 2009; Bezzi et al., 2013; 58 
Cheng et al., 2007; Sinha et al., 2010), subcellular localizations (Matsumoto et al., 2012; Nichols et al., 59 
2000; Tradewell et al., 2012) as well as the binding affinity to RNA molecules (Rho et al., 2007). 60 
Nevertheless, the role of arginine methylation in regulating protein stability remains unknown. Here we 61 
demonstrate that an RNA binding protein, RBM15, is methylated by PRMT1, which triggers its 62 
ubiquitylation by an E3 ligase CNOT4.  63 
 64 
RBM15 belongs to the Split Ends (Spen) family of proteins. Spen proteins are evolutionally conserved 65 
RNA binding proteins, which are involved in transcriptional regulation of NOTCH, WNT and MAPK signal 66 
transduction pathways (Chang et al., 2008; Chen and Rebay, 2000; Oswald et al., 2002; Rebay et al., 67 
2000; Su et al., 2015). Recently SPEN and RBM15 have been shown to be essential for Xist-mediated X 68 
chromosome inactivation (Chu et al., 2015; McHugh et al., 2015; Minajigi et al., 2015; Moindrot et al., 69 
2015; Monfort et al., 2015). Genetic studies in Drosophila have shown that spen is required for cell-fate 70 
decision during development (Kolodziej et al., 1995). FPA, the RBM15 homolog in Arabidopsis, controls 71 
flowering via regulating alternative polyadenylation of antisense RNAs at the FLC locus (Hornyik et al., 72 
2010). RBM15 is essential for the development of multiple tissues in mouse knockout models, in 73 
particular, for the maintenance of the homeostasis of long-term hematopoietic stem cells and for 74 
megakaryocyte (MK) and B cell differentiation (Niu et al., 2009; Raffel et al., 2009; Xiao et al., 2015). 75 
Furthermore, RBM15 is involved in the chromosome translocation t(1;22) which produces the RBM15-76 
MKL1 fusion protein associated with acute megakaryoblastic leukemia (AMKL) (Ma et al., 2001; Mercher 77 
et al., 2001).  78 
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 79 
Spen proteins consist of two domains: an RNA binding domain and a SPOC (Spen Paralog and Ortholog 80 
C-terminal) domain. Previously, SPEN proteins such as RBM15 and SHARP have been shown to use 81 
the SPOC domains to recruit histone deacetylases for transcriptional regulation of Notch pathway and 82 
steroid receptor-dependent transcriptional regulation, and to recruit MLL complexes to promoters for 83 
histone H3K4 methylation (Ariyoshi and Schwabe, 2003; Lee and Skalnik, 2012; Ma et al., 2007; Oswald 84 
et al., 2002; Shi et al., 2001; Xiao et al., 2015). Additionally, RBM15 is also involved in RNA export 85 
(Uranishi et al., 2009; Zolotukhin et al., 2008; Zolotukhin et al., 2009). RBM15 resides mainly within 86 
nuclear RNA splicing speckles by confocal microscopy (Horiuchi et al., 2013b), suggesting that RBM15 is 87 
involved in RNA splicing. However, how spen proteins control cell differentiation is not described at 88 
molecular level. 89 
 90 
In this report, we linked cellular differentiation to RBM15-regulated RNA metabolism using 91 
megakaryocyte differentiation as a model. We demonstrated that RBM15 binds to specific introns of pre-92 
mRNA of genes such as RUNX1, GATA1 and TPOR (aka c-MPL or MPL), which play critical roles in 93 
megakaryocyte differentiation, and to 3’UTRs of genes involved in RNA splicing and metabolic 94 
regulation. Reducing RBM15 protein concentration by PRMT1-mediated methylation favors the 95 
production of the alternatively spliced isoforms: RUNX1a, GATA1s and c-MPL-exon9-, a truncated c-96 
MPL isoform. We also found that RBM15 promotes megakaryocyte maturation in human primary cells. 97 
Therefore, PRMT1-RBM15 pathway fine-tunes cell differentiation via controlling the RBM15 protein 98 
concentration.  99 
 100 
Results 101 
 102 
RBM15 is methylated by PRMT1 103 
 104 
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In AMKL, MK differentiation is blocked. Gene expression data from AMKL patient samples (Bourquin et 105 
al., 2006) shows a higher PRMT1 expression level than other types of acute myeloid leukemia. 106 
Furthermore, high expression of PRMT1 is correlated with poor survival rate in acute myeloid leukemia 107 
(Figure 1-figure supplement 1). These clinical data strongly support that PRMT1 might be a key player 108 
in leukemogenesis. We applied bioorthogonal profiling of protein methylation (BPPM) technology (Figure 109 
1-figure supplement 2) (Wang et al., 2011) to identify proteins methylated by PRMT1 in 110 
megakaryocytes. We found that RBM15 is methylated at R578 by mass spectrometry analysis (Figure 1-111 
figure supplement 3A). Alignment of the RBM15 sequences covering the methylation site shows that 112 
the methylation site is conserved across diverse species (Figure 1A) and downstream of the RBM15 113 
RNA binding domains (Figure 1-figure supplement 3B). 114 
 115 
We validated that two generic antibodies against mono-methyl arginine proteins and against di-methyl 116 
arginine proteins (Cell Signaling Inc.), can recognize the methylated peptides from RBM15 (NP_073605) 117 
R578 region specifically in dot blots (Figure 1-figure supplement 3C&D). We observed that affinity 118 
purified Flag-tagged RBM15 protein is more efficiently methylated than the R578K mutant in western 119 
blots in transfected 293T cells (Figure 1B, compare lanes 1 and 2) as well as in leukemia cells (Figure 120 
1-figure supplement 3E). Given that the R578 is the last arginine in the RDRDRD repeat, we mutated 121 
all three arginines, but we still detected low methylation background indicating other arginine residues 122 
not in the repeat are methylated (Figure 1-figure supplement 3F). 123 
 124 
To determine whether PRMT1 is responsible, we overexpressed the two major isoforms of PRMT1 (V1 125 
i.e. Q99873 and V2 i.e. Q99873-3) respectively in 293T cells together with wild type RBM15 (Figure 1C). 126 
Overexpressing either isoform enhanced the mono-methylation of RBM15 (Figure 1C, compare lanes 1, 127 
2 and 3) and the V2 dimethylated RBM15 more effectively than the V1. Given that the V2 contains 128 
additional amino acids in the N terminal region relative to V1 (Figure 1D), it is striking that the PRMT1 V2 129 
is primarily responsible for the dimethylation of RBM15 in vivo (Figure 1C).  130 
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 131 
In vitro methylation assays showed that the RBM15 peptide was dimethylated as efficiently as the 132 
histone H4 peptide without monomethylated peptides detected (Figure 1-figure supplement 3G). We 133 
then used purified Flag-RBM15 from 293T cells to conduct in vitro methylation assays. Only the wild type 134 
RBM15 protein but not the R578K mutant was effectively dimethylated by PRMT1 in vitro (Figure 1E). 135 
These results together with in vivo methylation data collectively argue that mono-methylated RBM15 is a 136 
transient intermediate in vivo.  137 
 138 
To confirm that PRMT1 is responsible for in vivo methylation, we made MEG-01 stable cell lines 139 
expressing doxycycline-inducible shRNA against PRMT1. We detected the methylated form of RBM15 140 
with both mono-methyl and dimethyl antibodies. Reducing the expression of PRMT1 decreased the 141 
methylation level of the endogenous RBM15 (Figure 1F). When the leukemia cells were treated with 142 
DB75 (a PRMT1 inhibitor) (Yan et al., 2014), RBM15 methylation was reduced (Figure 1G). The 143 
methylation of RBM15 was further confirmed by an antibody raised against dimethylated RBM15 at R578 144 
(Figure 1-figure supplement 4). Therefore, we concluded that PRMT1 enzymatic activity is responsible 145 
for the methylation of RBM15 at R578. RBM15 might be methylated by other PRMTs and at other sites 146 
since some methylation signals especially the monomethylation signals are present despite PRMT1 147 
knock-down or inhibition and in the R578K mutant respectively. Nevertheless the PRMT1-dependent 148 
R578 methylation forms the majority of dimethylated species.  149 
 150 
RBM15 protein stability is determined by its methylation status  151 
 152 
When RBM15 was co-expressed together with PRMT1, RBM15 protein level was reduced. Strikingly, the 153 
V2 isoform (detected by V2 specific antibody) caused a greater reduction of RBM15 protein level (Figure 154 
2A), which coincided with the PRMT1 V2’s capability for RBM15 dimethylation (Figure 1C). To further 155 
confirm that methylation triggers protein degradation, we used non-specific methyltransferase inhibitors 156 
7 
(adox + MTA) (Figure 2B, left panel) as well as DB75 (Figure 2B right panel) to treat MEG-01 cells. 157 
Consistently, PRMT1 knockdown increased RBM15 protein level (Figure 2C, left panel) but not the 158 
RBM15 mRNA level (Figure 2C, right panel) in MEG-01 cells as well as in other leukemia cells (data not 159 
shown). Conversely, overexpression of PRMT1 V2 (Figure 2D, left panel) reduced RBM15 protein level. 160 
Given that the RBM15 mRNA levels in PRMT1 knockdown cells and in PRMT1 overexpressing cells 161 
were the same as in the control MEG-01 cells (Figure 2D middle and right panels), we concluded that 162 
PRMT1 controls RBM15 at protein level. Finally we observed that the specific knockdown of PRMT1 V2 163 
resulted in higher RBM15 protein level (Figure 2E). Taken together, we concluded that the PRMT1 V2 164 
enzymatic activity plays a major role in regulating the stability of the RBM15 protein.  165 
 166 
When we co-expressed RBM15 R578K together with PRMT1 V2 protein in 293T cells, we found that the 167 
mutant protein remained stable regardless of overexpression of PRMT1 V2 (Figure 2F, compare lanes 4 168 
and 2). Thus, methylation of RBM15 at R578 is the direct cause for protein degradation. To further 169 
determine whether RBM15 degradation is affected by methylation on R578, we compared the half-life of 170 
the wild type versus the mutant RBM15 proteins. The Flag-tagged RBM15 mutant has longer half-life 171 
compared with the wild type RBM15 (Figure 2G). Tag does not affect protein stability as the tagged 172 
RBM15 and endogenous RBM15 have similar half-life.  173 
 174 
RBM15 degradation is an ubiquitylation-mediated process 175 
 176 
We showed that the proteasome inhibitor MG132 stabilized the RBM15 protein, which indicates that the 177 
degradation is mediated by ubiquitylation (Figure 3A). To further confirm that the RBM15 protein is 178 
ubiquitylated, we used nickel beads to purify the poly-ubiquitylated form of RBM15 under denaturing 179 
conditions from 293T cells expressing the poly-histidine tagged ubiquitin and Flag-tagged RBM15 180 
(Figure 3B).  181 
 182 
8 
To investigate whether methylation of RBM15 by PRMT1 is required for RBM15 ubiquitylation, we 183 
mutated the methylation site to lysine. Compared with the wild type RBM15 protein, significantly less 184 
R578K RBM15 protein was modified by ubiquitin (Figure 3C compare lanes 4 and 5,) when the 185 
respective plasmids were co-expressed in 293T cells. Thus, methylation on R578 for protein 186 
ubiquitylation is one major pathway for RBM15 degradation. To validate endogenous RBM15 is also 187 
ubiquitylated in a methylation-dependent manner, we treated the MEG-01 cells with PRMT1 inhibitor 188 
DB75. After DB75 treatment, less ubiquitylated RBM15 protein were observed (Figure 3D).  189 
 190 
CNOT4 is the E3 ligase responsible for RBM15 ubiquitylation  191 
 192 
PRMT1 has been shown to physically interact with the CCR4-NOT complex via the CAF1 (aka CNOT7) 193 
subunit for RNA export (Kerr et al., 2011; Robin-Lespinasse et al., 2007). Furthermore, CNOT4, a 194 
subunit of the CCR4-NOT complex, has been shown to be an E3 ligase (Albert et al., 2002). To examine 195 
whether CNOT4 might be responsible for ubiquitylation of RBM15, we co-expressed CNOT4 with RBM15 196 
in 293T cells. Strikingly, when RBM15 was co-expressed with PRMT1 and CNOT4, RBM15 was more 197 
severely ubiquitylated than RBM15 expressed with PRMT1 or CNOT4 alone (Figure 3E). We also 198 
detected the interaction between PRMT1 and RBM15 wild type and mutant proteins in 293T cells 199 
(Figure 3E lanes 3,4 and 7,8). Moreover, only the wild type not the mutant RBM15 interacted with HA-200 
tagged CNOT4 (Figure 3E lane 3, 4). In Figure 3E and Figure 3C, we showed that the RBM15 R578K, 201 
which cannot be methylated by PRMT1, had significantly less ubiquitylated RBM15 protein. This data 202 
strongly suggest that the methylation is required for subsequent ubiquitylation by the CNOT4 complex.   203 
 204 
To further confirm that CNOT4 is the enzyme responsible for endogenous RBM15 ubiquitylation, we 205 
showed that CNOT4 knockdown (western blot in Figure 3F and real-time PCR in Figure 3-figure 206 
supplement 2A) increased the amount of endogenous RBM15 protein in MEG-01 cells (Figure 3F). 207 
When MEG-01 cells were treated with DB75, CNOT4 knockdown did not further stabilize the RBM15 208 
9 
protein (Figure 3F). These results confirm that methylation is required for the subsequent degradation of 209 
the RBM15 protein. We used CRISPR technology to knockout one allele of CNOT4 gene in 293T cells. 210 
We also found that removal of one allele of CNOT4 stabilized the endogenous RBM15 protein levels 211 
(Figure 3-figure supplement 2B&C).  212 
 213 
We then purified the RBM15 and CNOT4 proteins (Figure 3-figure supplement 1) to do in vitro 214 
ubiquitylaton assay. The methylated RBM15 protein (Flag-tagged) by PRMT1 was more efficiently 215 
ubiquitylated by CNOT4 than the purified RBM15 R578 in vitro (Figure 3G compare lane 5 to lane 3). 216 
Taken together, we demonstrated that the RBM15 protein stability is negatively regulated by PRMT1-217 
mediated methylation at R578, and CNOT4 is an E3 ligase responsible for degrading the methylated 218 
RBM15. To understand further whether the methylation site on RBM15 is sufficient to bind to CNOT4 219 
complex, we synthesized two RBM15 peptides covering the arginine methylation sites to pull-down 220 
CNOT4 from cell extract. The di-methylated peptide bound specifically to the CNOT4 protein (Figure 221 
3H), which is agreeable with the coimmunprecipitation data in Figure 3E showing that CNOT4 only 222 
interacted with wild type RBM15 proteins. This result implies that either CNOT4 or subunits in the 223 
CNOT4 complex directly interacts with RBM15 via the methylation mark.  224 
 225 
PRMT1 V2 inhibits MK maturation via a methylation-ubiquitylation switch on RBM15  226 
 227 
PRMT1 RNA levels were measured in isolated mouse long-term hematopoietic stem cells (LT-HSC), 228 
short-term hematopoietic stem cells (ST-HSC), progenitor cells and terminally differentiated lineages. 229 
PRMT1 expression level was the lowest in LT-HSC and higher especially in myeloid progenitor cells 230 
(Figure 4-figure supplement 1A-D). Megakaryocyte-erythrocyte progenitor (MEP) cells expressed the 231 
highest level of PRMT1. We also checked the expression of PRMT1 and RBM15 in human cells with 232 
HemaExplorer (Bagger et al., 2013). The expression profiles of PRMT1 and RBM15 in different lineages 233 
are shared between humans and mice (Figure 4-figure supplement 1E-G). The mRNA level of RBM15 234 
10 
does not change as dramatically as that of PRMT1 among different lineages, which implies that post-235 
transcriptional modification such as arginine methylation of RBM15 might contribute to the regulation of 236 
RBM15 protein levels. 237 
 238 
To understand the biological functions of PRMT1 in MK differentiation, we used PMA to stimulate MEG-239 
01 cells into mature MK cells (Ogura et al., 1988). Upon PMA stimulation, we observed upregulation of 240 
the RBM15 protein within 12 hours and simultaneous down-regulation of the PRMT1 V2 protein (Figure 241 
4A left and middle panels). During the incubation period, neither the RBM15 mRNA level (Figure 4A, 242 
right panel) nor the total PRMT1 protein level (mainly V1 isoform) changed more than 1.5 folds, 243 
nevertheless we found that RBM15 protein level was significantly increased. The methyl-RBM15 level 244 
reduced coinciding with the decrease of the isoform V2 protein (detected by V2-specific antibody). Thus 245 
we conclude the isoform V2 –mediated methylation is one mechanism for upregulating RBM15 protein 246 
level, although we cannot rule out other possibilities such as enhanced protein translation. To assess 247 
RBM15 effects on MK differentiation, we ectopically expressed the wild type and the R578K mutant 248 
proteins in MEG-01 cells by retroviruses respectively. After stimulation with PMA for 7 days, more CD41+ 249 
cells (Figure 4B) as well as higher levels of polyploidy (Figure 4C) were detected. In comparison to wild 250 
type RBM15, the RBM15 R578K generated more CD41+ cells, which may be explained by increased 251 
RBM15 R578K stability (Figure 3).  252 
 253 
However, the cell line differentiation system can only mimic certain aspects of normal megakaryopoiesis. 254 
For example, we cannot detect CD42 in MEG-01 cells upon PMA stimulation. Therefore, we performed 255 
MK differentiation assays with adult human CD34+ cells. Compared to the control, DB75 treated cells 256 
produced a higher percentage of CD61+CD42+ mature MK cells (Figure 4D). Conversely, ectopic 257 
expression of PRMT1 V2 in CD34+ cells promoted the generation of single positive CD61+ MK progenitor 258 
cells but blocked MK cell maturation (Figure 4E). Like PRMT1 overexpression, knockdown of RBM15 by 259 
shRNAs blocked MK maturation (Figure 4F, Figure 4-figure supplement 2), and overexpression of 260 
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both RBM15 and its mutant promoted the maturation of CD34+ cells (Figure 4G). Overexpression of 261 
RBM15 or RBM15 R578K rescued megakaryocyte differentiation in CD34+ cells expressing PRMT1 V2 262 
(Figure 4H). Taken together, PRMT1 controls megakaryopoiesis via controlling RBM15 protein levels.  263 
 264 
RBM15 binds to pre-mRNA of genes in megakaryocyte differentiation  265 
To understand how RBM15 protein level controls megakaryocytic differentiation, we affinity purified 266 
RBM15-associated proteins from 293T cells, which express endogenous RBM15 protein. Mass 267 
spectrometry analysis showed that RBM15 was associated with ASH2 and WTAP, two known RBM15-268 
bound proteins (Horiuchi et al., 2013a; Lee and Skalnik, 2012) as well as proteins involved in RNA 269 
splicing (Figure 7-source file 1), which is consistent with prior findings that RBM15 resides in nuclear 270 
splicing speckles (Horiuchi et al., 2013b). Thus, we reasoned that RBM15 might regulate alternative 271 
splicing. We performed RIP (RNA immunoprecipitation assay) under stringent wash conditions with an 272 
RBM15 antibody recognizing the N-terminal region, followed by RT-PCR to detect genes known 273 
important for megakaryocyte differentiation. We detected the bindings of RUNX1, GATA1 and c-MPL 274 
mRNAs with RBM15, while we did not detect that of control GAPDH mRNA (Figure 5A). Then we took 275 
an unbiased approach to identify global RBM15 target genes using RIP-seq. We have identified 1297 276 
genes to which RBM15 binds directly (Figure 5-source file 1). 55% of RBM15 binding sites are in 277 
intronic regions, and 41% are in 3’UTR regions with the remainder in 5’UTRs and CDS elements (Figure 278 
5B). Gene ontology pathway analysis showed RBM15 regulates genes involved in differentiation and 279 
signal transduction via binding to intronic regions whereas genes involved in RNA splicing and metabolic 280 
pathways via binding to 3’UTRs (Figure 5C&D). We found that overexpression of PRMT1 V1 and V2 281 
isoforms as well as reducing the expression level of RBM15 enhanced mitochondria biogenesis in MEG-282 
01 cells (Figure 5-figure supplement 3), which implies that PRMT1-RBM15 axis regulates metabolism. 283 
Among the RBM15 targeting genes with binding sites in introns are transcription factors known to be 284 
important for megakaryocyte differentiation: RUNX1, GATA1, and TAL1 (Figure 5-figure supplement 285 
1,2). Although the transcription factor LEF1 has not yet been linked to MK differentiation, LEF1 has been 286 
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shown to interact with RUNX1 genetically and biochemically (Daga et al., 1996; Mayall et al., 1997; 287 
McNerney et al., 2013). RBM15 binding peaks on c-MPL pre-mRNA in the RIP-seq data (Figure 5-figure 288 
supplement 2). 289 
To further investigate how RBM15 regulates alternative RNA splicing, we performed RNA-seq assays 290 
with RNA isolated from MEG-01 cells with or without RBM15 knockdown. The gene expression profile 291 
analysis showed that RBM15 knock-down alters metabolism and endoplasmic reticulum stress response 292 
pathways as well as proteins involved in chromatin assembly (Figure 5-source file 2). We then used two 293 
programs (DEXSeq and MISO) to detect the alterations of exon usage. DEXSeq detected 9704 294 
differential exon usage events with P value lower than 0.05 and fold change higher than 1.2 fold. The 295 
MISO program detected 2027 differential exon usage events with Bayes factor higher than 2. RBM15 296 
regulates differential exon usage in all eight categories in either directions (Figure 5 E&F). Significant 297 
exon usage changes of 156 genes in the RIP-seq group were detected by both programs (Figure 5-298 
source file 3) including transcription factors RUNX1, GATA1, STAT5A, TAF9, TAL1, LEF1 and ZNF160 299 
as well as chromatin remodeling factors such as macroH2A, DEK, BRD9, TLE3, NCOR1 and HDAC4. 300 
RUNX1, GATA1, STAT5A and TAL1(SCL) are well-studied transcription factors for their roles in 301 
megakaryocyte differentiation (Crispino, 2005; Olthof et al., 2008; Tijssen et al., 2011). Signal 302 
transduction genes important for hematopoiesis such as RPTOR and CDC42 (Kaushansky and 303 
Kaushansky, 2014) were found on the list as well. Therefore, RBM15 protein level may affect 304 
hematopoiesis via multiple pathways. At a molecular level, RBM15 not only affects alternative RNA 305 
splicing such as RUNX1, GATA1, TAL1, STAT5A, LEF1 but also affects UTR utilization (e.g. TAL1), 306 
mixed exon usage (e.g. CDC42) and intron retention (e.g. macroH2A) (Figure 5-figure supplement 4). 307 
The MISO program was used to analyze how GATA1 is alternatively spliced. After knocking down 308 
RBM15, we found skipping of exon 2 on GATA1 (Figure 5G) and validated our results by resolving 309 
GATA1 isoforms in an agarose gel (Figure 5H). 310 
 311 
RBM15 regulates alternative splicing of genes important for megakaryocyte differentiation  312 
13 
GATA1 has two different isoforms: full length GATA1 (GATA1fl), and short form GATA1 (GATA1s), which 313 
is generated by skipping the exon 2 (Rainis et al., 2003). In Down syndrome leukemia, GATA1fl mRNA 314 
translates the GATA1s protein when mutations on GATA1fl mRNA create an alternative translation start 315 
site. Using isoform specific probes targeting to the exon junctions of GATA1s and GATA1fl to perform 316 
real time PCR assays, we found that reducing RBM15 protein level favored the accumulation of GATA1s 317 
as the ratio of GATA1fl/GATA1s was reduced (Figure 6A top panel). Conversely, overexpression of 318 
RBM15 reversed the ratio of GATA1fl/GATA1s in favor of GATA1fl. The RBM15 R578K protein, which is 319 
more stable, altered the ratio more than the wild type RBM15. Furthermore, overexpression of V2 in 320 
MEG-01 cells reduced the ratio of GATA1fl to GATA1s similar to the effect of RBM15 knockdown. When 321 
we used inducible cell lines to knockdown PRMT1, we observed a higher ratio of GATA1fl/GATA1s like 322 
in cells overexpressing RBM15 (Figure 6A). To further probe the importance of PRMT1 enzymatic 323 
activity in alternative splicing, we used PRMT1 inhibitor DB75 to treat MEG-01 cells, CMK cells and CMY 324 
cells which all derived from AMKL leukemia patients. All three AMKL cell lines had higher 325 
GATA1fl/GATA1s ratio when treated with DB75 (Figure 6-figure supplement 1). Both isoforms of 326 
GATA1 can support megakaryocyte differentiation, but only GATA1s supports unrestricted proliferation 327 
due to losing the interaction with E2F1 (Li et al., 2000). Therefore, fine-tuning the ratio between two 328 
different GATA1 isoforms regulates the balance between proliferation and differentiation of 329 
megakaryocyte progenitors.  330 
.  331 
RUNX1 is required for megakaryocyte differentiation as shown in a conditional RUNX1 knockout mouse 332 
model (Ichikawa et al., 2004). Individual RUNX1 isoforms regulate hematopoiesis differently (Komeno et 333 
al., 2014b; Tsuzuki and Seto, 2012). RBM15 bound to RUNX1 pre-mRNA in intronic regions and in 334 
3’UTR (Figure 5-figure supplement 2). The MISO program found that RUNX1 is alternatively spliced by 335 
skipping exon 6 which generates RUNX1-Exon 6- protein. Overexpression of RUNX1-Exon 6- in 336 
transgenic mice leads to reduced pool of hematopoietic stem cells (Komeno et al., 2014a)(Figure 5 337 
figure supplement 4). Given that RBM15 binds to the 3’UTR in exon 8 as well as to intronic regions 338 
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flanking exon 7a, we investigated whether knockdown of RBM15 causes alternative 3’UTR usage to 339 
generate RUNX1a which uses exon7a’ 3’UTR. In RBM15 knock-down MEG-01 cells, the ratio between 340 
RUNX1a and RUNX1b,c switched in favor of RUNX1a. RUNX1a which lacks the transactivation domain 341 
acts as a dominant negative regulator to antagonize the function of RUNX1b,c (Ran et al., 2013a). 342 
Increasing the amount of RUNX1a may interfere with the differentiation into mature megakaryocytes. 343 
Consistent with RBM15 knockdown data, we showed that overexpression of RBM15 as well as 344 
knockdown of PRMT1 tilted the isoform balance toward RUNX1b,c. In agreement with the PRMT1 345 
knockdown data, overexpression of PRMT1 V2 switched the ratio in favor of RUNX1a (Figure 6A middle 346 
panel).  347 
 348 
The thrombopoietin receptor (TPOR, aka. c-MPL) is upregulated during megakaryocyte differentiation. c-349 
MPL has at least 4 described isoforms in humans (Figure 6-figure supplement 2). Using reported 350 
primers (Li et al., 2000) to amplify cDNA from MEG-01 cells, we found an additional band on the PAGE 351 
gel, which was identified as an undescribed isoform lacking exon 9 (c-MPL-exon9-) through sequencing. 352 
The c-MPL-exon9- mRNA was predicted to yield a truncated protein (Figure 6-figure supplement 2). 353 
Thus we designed specific primer spanning the junction between exon 8 and exon 10 to detect c-MPL-354 
exon9- mRNA. We also used a pair of primers, the forward primer spanning exon 8 and exon 9 and 355 
reverse primer annealing to exon 9, to detect the full length MPL (i.e. c-MPL-exon 9+). The c-MPL-356 
exon9-/c-MPL-exon9+ ratio was higher in favor of c-MPL-exon9- (Figure 6A, bottom panel) when 357 
RBM15 protein level is reduced. Furthermore, when RBM15 or RBM15 R578K was overexpressed, the 358 
ratio is down in favor of c-MPL-exon9+. Given that c-MPL exon9+ is required for MK differentiation, the 359 
data further support for the positive role of RBM15 at megakaryocyte maturation. All other isoforms with 360 
part of exon 9 or with both exon 9 and 10 missing were spliced in the same way by RBM15-PRMT1 361 
pathway (Figure 6-figure supplement 3). Thus, RBM15 enhances the inclusion of exons to produce full-362 
length functional c-MPL like in RUNX1’s case. Consistent with our data, mouse Rbm15 regulates c-Mpl 363 
alternative splicing in the same fashion (Xiao et al., 2014) .  364 
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 365 
We monitored the isoform ratios using human adult CD34+ cells in pro-MK differentiation medium over a 366 
time course. We found that the GATA1fl/GATA1s ratio was increased, and the RUNX1a/RUNX1b,c ratio 367 
and c-MPL-exon9-/c-MPL-exon9+ ratio were decreased during the course of differentiation (Figure 6B). 368 
We observed that the isoform ratio changes in the DB75-treated CD34+ cells (Figure 6C) exactly like in 369 
the DB75-treated MEG-01 cells (Figure 6 figure supplement 1). Based on these data, we concluded 370 
that RBM15 regulates alternative RNA splicing of genes important for MK differentiation. By controlling 371 
the RBM15 protein dosage, PRMT1 thereby regulates MK differentiation.  372 
 373 
RBM15 controls alternative splicing via its interaction with SF3B1 374 
 375 
To understand the detailed mechanism of how RBM15 regulates alternative splicing, we identified 376 
RBM15-associated splicing factors such as SF3B1 and U2AF, known proteins in committed RNA splicing 377 
A complex that binds to branch point region (Figure 7-source file 1). Furthermore, we confirmed the 378 
interaction between SF3B1 and RBM15 by co-immunoprecipitation with anti-Flag antibody for Flag-379 
tagged RBM15 proteins (Figure 7A) and with anti-RBM15 antibody (Figure 7B). To further confirm that 380 
PRMT1 enzymatic activity is important for alternative RNA splicing, we inhibited PRMT1 activity with 381 
DB75 or shPRMT1. The interaction between SF3B1 and RBM15 was subject to methylation regulation. 382 
One simple explanation is that RBM15 might recruit more SF3B1 because of more RBM15 and SF3B1 383 
proteins available. It is also possible that methylation might be directly involved in RBM15 and SF3B1 384 
interaction. Given that co-immunoprecipitation assays cannot distinguish the direct and indirect protein-385 
protein interaction in a protein complex, RBM15’s interaction with SF3B1 only implies that RBM15 386 
recruits the 3’RNA splicing complex. Since SF3B1 is often mutated in leukemia cells, we sequenced the 387 
SF3B1 gene in MEG-01 cells and confirmed that SF3B1 was not mutated in this cell line. Thus the 388 
interaction is between two wild type proteins. 389 
 390 
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From the RIP-seq data, we found that RBM15 was specifically associated with intronic region close to 391 
5’end of the intron 1 of GATA1 (Figure 7C). We validated the RIP-seq data by real-time PCR with primer 392 
sets covering the GATA1 intron 1. Analysis of immunoprecipitated RNA associated with SF3B1 indicated 393 
that SF3B1 also preferentially bound to the same region that RBM15 bound to. Furthermore, with RBM15 394 
knockdown, less SF3B1 was associated with GATA1 pre-mRNA (Figure 7D). On the other hand, 395 
GAPDH has similar level of SF3B1 binding to introns regardless of RBM15 expression level. Thus, 396 
RBM15 is responsible for recruiting SF3B1 to pre-mRNA molecules. In this case, RBM15 facilitates the 397 
inclusion of GATA1 exon 2. For c-MPL pre-mRNA, RBM15 preferentially bound to the intron 8 and intron 398 
10 of the pre-mRNA molecules with two distinct peaks (Figure 7E left), while SF3B1 (Figure 7E right) 399 
did bind to regions between the two RBM15 bound peaks at higher level than other regions. When we 400 
used RBM15 knockdown MEG-01 cells to do SF3B1 RIP on c-MPL pre-mRNA, we found that SF3B1 401 
binding was significantly reduced in RBM15 bound regions (Figure 7E right). In this case, RBM15 402 
functions as a splicing enhancer for inclusion of exons 9 and 10. In aggregate, these data show that 403 
RBM15 is responsible for recruiting SF3B1 containing branch point recognition complex to introns, and 404 
methylation controls the RBM15 dosage thereby controls alternative RNA splicing (Figure 7F). 405 
 406 
Discussion 407 
We report here that PRMT1 V2 dimethylates RBM15 within the sequence (LYRDRDR(me2)DLY). 408 
Although the most common sequence for arginine methylation is arginine flanked by glycines, PRMT1 409 
has been previously reported to methylate arginines in PGC1-α and in RUNX1 flanked by other amino 410 
acids (Teyssier et al., 2005; Zhao et al., 2008). Recent proteomics work further proves that the 411 
methylation motif can be very diverse (Guo et al., 2014). Since we can still detect a low level of mono-412 
methylation signal after R578K mutation, we believe that the mono-methylation signals come from 413 
additional arginines methylated by PRMT1 or other arginine methyltransferases. Protein mono-414 
methylation sites in general are redundant and prevalent which are catalyzed by multiple protein arginine 415 
methyltransferases (Dhar et al., 2013). Nevertheless, these potential sites are not involved in 416 
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methylation-mediated ubiquitylation. Another surprising result is that the V2 isoform, which contains 417 
additional amino acids on the N-terminus, primarily dimethylates RBM15 in vivo (Figure 1C). Data from 418 
PMA treated MEG-01 cells argue that the V2 isoform is more relevant to MK maturation (Figure 4A). 419 
Although it has been demonstrated that V1 and V2 have different substrate specificities in vivo (Goulet et 420 
al., 2007), RBM15 is the first V2 specific substrate identified. Of note, the V2 isoform only comprises less 421 
than 5% of total PRMT1 level, but V2 is mainly responsible for oncogenic activities in colon and breast 422 
cancers (Baldwin et al., 2012; Papadokostopoulou et al., 2009). We cannot completely exclude a role for 423 
V1 in RBM15 methylation due to the inability to knockdown V1 specifically. Because developing inhibitors 424 
specific for PRMT1 V2 isoform will potentially alleviate off-target effects, which remain a major 425 
impediment for developing anti-PRMT1 inhibitors, our data offers new clues on how to achieve V2 426 
specific inhibition. RBM15 is involved in chromosome translocation t(1;22), which produces the fusion 427 
product RBM15-MKL1 (Ma et al., 2001; Mercher et al., 2001). Whether the fusion protein, which retains 428 
R578, is methylated by PRMT1 is still an unanswered question.  429 
 430 
It was previously reported that methylation of a transcriptional coactivator p/CIP by PRMT4 or CARM1 431 
leads to its degradation, however the mechanism was incomplete (Naeem et al., 2007). Here we report 432 
that PRMT1 methylation triggers protein degradation via ubiquitylation by the E3 ligase CNOT4. CNOT4 433 
is loosely associated with the other subunits of CCR4-NOT complex (Lau et al., 2009). Apart from 434 
deadenylation activity of other CCR4-NOT complex, CNOT4 has been shown to ubiquitylate a histone 435 
demethylase Jhd2, which is responsible for erasing the histone H3K4 trimethylation marks in yeast 436 
(Mersman et al., 2009). Given that RBM15 interacts with histone methyltransferases complexes to 437 
maintain histone H3K4 methylation level (Lee and Skalnik, 2012; Xiao et al., 2015), our data provide new 438 
insights into a potential crosstalk between methyltransferases and demethylases.  439 
 440 
Recently the E3 ligase WWP2 has been shown to recognize the methylated lysine in SOX2 through its 441 
HECT domain (Fang et al., 2014). Given that CNOT4 is within a large CCR4-NOT complex with 9 442 
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subunits, we have not determined which domain in CNOT4 or other subunits of CCR4-NOT complex 443 
recognizes the methylated RBM15. The peptide pull-down experiments strongly support that methylated 444 
region on RBM15 is sufficient for binding to CNOT4. Since we found that the RING domain on CNOT4 445 
alone was not sufficient for binding to methylated RBM15 (data not shown), it is possible that more than 446 
one region on CNOT4 or other subunits in CCR4-NOT complex might interact with RBM15.  447 
 448 
In order to investigate the biological significance of PRMT1-mediated methylation of RBM15, we 449 
analyzed the role of PRMT1-RBM15 axis in hematopoiesis. Normal MK differentiation can be divided into 450 
two phases: from hematopoietic stem cells to MK progenitor cells and from MK progenitor cells into 451 
mature polyploidy MK cells. There are examples that genes such as ARHGEF1 important (ARHGEF1,2 452 
are in Figure 5-source file 1) for MK differentiation often play opposite roles at different phases (Gao et 453 
al., 2012; Smith et al., 2012). The number of MEP progenitor cells increases, while the polypoidy of 454 
mature megakaryocytes decreases in Rbm15 knockout mice (Niu et al., 2009). Consistent with this, 455 
RBM15 knockdown in human primary cells like Rbm15 knockdown in mice produces low percentage of 456 
mature megakaryocytes (Figure 4F). PRMT1 promotes the production of MEP cells, but PRMT1 has to 457 
be turned off to generate mature, polyploid CD41+/CD61+CD42+ MK cells. Because both PRMT1 and 458 
RBM15 are ubiquitously expressed in all tissues, PRMT1-RBM15 might regulate differentiation in the 459 
same fashion in other tissues such as cardiac tissue, spleen and placenta where RBM15 has been 460 
shown to be essential for development (Raffel et al., 2009).  461 
 462 
According to the Oncomine database (www.oncomine.com), PRMT1 is highly expressed in acute 463 
myeloid and lymphoid leukemia (AML and ALL) as well as in solid tumors (Rhodes et al., 2007). PRMT1 464 
accounts for 4% gene mutations, amplifications and deletions in solid tumors (see www.cbioportal.org) 465 
(Gao et al., 2013). The relevance of PRMT1 inhibition in cancer therapies is summarized in reviews 466 
(Greenblatt and Nimer, 2014; Yang and Bedford, 2013). The roles of PRMT1 in supporting cancer cell 467 
proliferation are shown in AML1-ETO and MLL-EEN initiated leukemia (Cheung et al., 2007; Shia et al., 468 
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2012). A PRMT1-mediated MK block may therefore be contributory to AMKL leukemogenesis. Apart from 469 
their functions in megakaryocyte differentiation, RUNX1, GATA1 and c-MPL as well as other epigenetic 470 
factors such as BRD4 found in this study are dysregulated in a broad spectrum of hematological 471 
malignancies as well as in solid tumors (Baratta et al., 2015; Crawford et al., 2008; Crispino, 2005; 472 
Harada et al., 2004; Pikman et al., 2006). Thus, dysregulation of PRMT1-RBM15 pathway might be a 473 
common mechanism in leukemia and solid tumors. 474 
 475 
The role of RNA splicing is increasingly appreciated in hematological malignancies (Cazzola et al., 476 
2013). The RNA splicing patterns vary widely from hematopoietic stem cells to progenitor cells in 477 
humans (Chen et al., 2014). Our studies offer mechanisms on how RNA splicing is regulated during 478 
hematopoiesis. RBM15 directly recruits the SF3B1 branch point recognition complex to introns. SF3B1 479 
has been found to have mutations in myelodysplastic syndrome and in leukemia (Yoshida et al., 2011). 480 
Given that SF3B1 knockout mouse cannot mimic defects seen in myelodysplastic syndromes (Wang et 481 
al., 2014), mutations in SF3B1 are likely gain-of-function mutations. Whether altered interactions 482 
between RBM15 and SF3B1 mutants contribute to hematological malignancies warrants future study.  483 
 484 
One direct consequence of RNA splicing is the altered concentration ratios between functional proteins 485 
and their alternatively spliced dominant negative counterparts. The physiological significance for multiple 486 
isoforms of c-MPL is to attenuate signaling from full-length c-MPL during megakaryocyte maturation. In 487 
transgenic mouse exclusively expressing full-length c-MPL, excessive production of platelets is observed 488 
(Tiedt et al., 2009). Abnormal expression of GATA1s and RUNX1a are associated with leukemia 489 
(Crispino, 2005; Liu et al., 2009). By controlling isoform ratios, HSCs fine-tune the lineage preference 490 
and the magnitude of lineage production during differentiation. This type of regulation is very important 491 
for HSCs to respond quickly to ever-changing environmental clues.  492 
 493 
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RBM15 by binding to introns flanking the alternatively spliced exons enhances the inclusion of the exons 494 
to produce full length c-MPL mRNA (Figure 7E). In the case of GATA1, RBM15 binds to intron 1 to 495 
recruit SF3B1 to the same location (Figure 7D). As a result, RBM15 enhances the inclusion of exon 2 to 496 
generate the GATA1fl mRNA (Figure 6A). RBM15 facilitate the production of more full length RUNX1b,c 497 
by skipping the exon which encodes RUNX1a. Knockdown RBM15 also facilitate the generation of 498 
RUNX1-exon6-. Based on our proteomic data, RBM15 binds to RNA binding proteins which are involved 499 
in RNA surveillance, transport and degradation (Figure 7-source file 1). Consistently, we also detected 500 
RBM15 association with matured mRNAs (Figure 5A). In addition, RBM15 associates with 501 
transcriptional elongation factors such as Tho2 and CTR9 besides its role in transcription initiation by 502 
positively regulating histone H3K4 methylation (Xiao et al., 2015). We speculate that RBM15 participates 503 
in regulating the whole life cycle of a messenger RNA. This is reminiscent of the functions of CCR4-NOT 504 
complex (Miller and Reese, 2012). RBM15 has been shown to be part of RBM20-mediated RNA splicing 505 
network in cardiomyocytes (Maatz et al., 2014; Raffel et al., 2009). Thus, RBM15 is involved in 506 
development of other tissues in addition to hematopoiesis. Further experiments to define the specificity 507 
and affinity of RBM15 binding sequences will help us to understand the mechanisms of alternative 508 
splicing mediated by RBM15.  509 
 510 
Apart from binding to introns, RBM15 binds to 3’UTR of metabolic enzymes, splicing factors as well as a 511 
few long noncoding RNA molecules and microRNAs (Figure 5-source file 2). Given that splicing factors 512 
can be involved in alternative RNA polyadenylation and RNA export, it is not surprising that RBM15 binds 513 
to 3’UTRs for alternative RNA polyadenylation, export as well as for RNA splicing (Castelo-Branco et al., 514 
2004; Kyburz et al., 2006). Analysis by the MISO program indicates that RBM15 regulates alternative 515 
RNA splicing of genes such as HK1 by binding to 3’UTR. In the future, deeper sequencing of RNA 516 
samples and performing high resolution PAR-CLIP assays (Hafner et al., 2010) with RBM15 antibodies 517 
will further define the RBM15-mediated RNA metabolism.  518 
 519 
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In summary, our findings demonstrated a new role for PRMT1 in regulating RNA metabolism. Given that 520 
both RBM15 and PRMT1 are evolutionarily conserved proteins from plants to mammals, our studies on 521 
the PRMT1-RBM15 pathway offer mechanistic insights into how RBM15 may regulate cell fate decision 522 
in multi-cellular organisms at post-transcriptional levels. 523 
 524 
Methods  525 
Using BPPM technology to profile PRMT1 methylated proteins 526 
To reveal proteome-wide substrates of protein methyltransferases such as PRMT1 in the context of 527 
complex cellular components, we took advantage of the emerging Bioorthogonal Profiling of Protein 528 
Methylation (BPPM) technology (Luo, 2012; Wang and Luo, 2013). In BPPM, designated 529 
methyltransferases are engineered to process sulfonium-alkyl SAM analogues as alternative cofactors 530 
and thus transfer the distinct sulfonium alkyl handles to substrates (Figure 1-figure supplement 2A). 531 
Because the alkyl handles contain a terminal-alkyne for the azide-alkyne Huisgen cycloaddition (the click 532 
reaction), we can then couple the chemical moiety with a biotin-containing azide probe for amenable 533 
target enrichment and characterization. With the previously-identified Y39F-M48G PRMT1 mutant and 534 
the matched 4-propargyloxy-but-2-enyl SAM (Pob-SAM) as BPPM reagents (Wang et al., 2011), RBM15 535 
in the context of Meg-01 cells was readily labeled by the enzyme-cofactor pair, modified by a biotin-536 
containing azide probe, and enriched by streptavidin beads (Figure 1-figure supplement 2B). As the 537 
negative control, the label efficiency dropped significantly in the absence of the Y39F-M48G PRMT1 538 
variant. The tagged proteins were subsequently purified with streptavidin beads for mass spectrometry 539 
analysis. RBM15 was identified among the methylated proteins. We verified the mass spectrometry data 540 
with direct western blot with RBM15 antibody against biotinylated proteins (Figure 1-figure supplement 541 
2C). To further map the RBM15 methylation sites, Flag tagged RBM15 protein was purified from 542 
transient transfected 293T cells for tandem mass spectrometry analysis. A mono-methylation site was 543 
found at R578, which lies between the RNA binding domain and the SPOC domain (Figure 1-figure 544 
supplement 3A).  545 
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Plasmids: 546 
The human RBM15 cDNA in pCDNA3 vector was kindly provided by Dr. Barbara Felber (NIH). The 547 
nucleotide sequences of all constructs were verified by sequencing. The retrovirus expression vector 548 
Migr1 was used to overexpress RBM15 and its mutant. pTripZ (Openbiosystems) was used to 549 
overexpress the PRMT1-V1 and PRMT1-V2 proteins by replacing RFP with PRMT1-V1 or PRMT1-V2 550 
cDNA. The lentivirus expressing shRNA against PRMT1, RBM15, and CNOT4 were purchased from 551 
Openbiosystems (ThermoScientific Inc.). The sequences are available in Supplementary file 1. pRS 552 
and pRS-shPRMT1-V2 plasmids were reported previously (Baldwin et al., 2012).  553 
Viral production and transduction 554 
For virus production, 293T cells were cotransfected with retroviral or lentiviral plasmids with helper 555 
plasmids as described (Vu et al., 2013). Cells stably expressing PRMT1-V1 and PRMT1-V2 or 556 
knockdown RBM15 or PRMT1 were selected with 5 µg/ml puromycin, and GFP-positive cells stably 557 
expressing Flag-RBM15 and Flag-RBM15-R were sorted on a FACSAria cell sorter. BD FACS 558 
LSRFortessa was used to do FACS analysis. 559 
New isoform of c-MPL  560 
The gene bank number for this new c-MPL isoform is KF964490.   561 
Cell culture 562 
HEK293T cells were cultured in DMEM supplemented with 10% FBS and transient transfected by 563 
lipofectamine 2000 (Invitrogen, Grand Island, USA). The pcDNA3 empty vectors were added to all 564 
transfections to balance total DNA. The human leukemic cell line MEG-01 was cultured in RPMI1640 565 
medium containing 10% FBS with 100U/ml penicillin and 100ug/ml streptomycin. The generic methyl-566 
transferase inhibitors: Adox (adenosine, periodate oxidized, Sigma, #7154) and MTA (5’-Deoxy-5’-567 
(methylthio) adenosine, Sigma, #D5011) were purchased from Sigma, St. Louis, USA. PMA (20nM) was 568 
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added to stimulate Meg-01 cells to differentiate into megakaryocytes. The differentiated cells were 569 
labeled with anti-CD41 antibody and CD42 antibody (BD) and analyzed by FACS Fortessa machine. 570 
Coimmunoprecipitation and Immunoblot analysis 571 
Transfected 293T cells from 10-cm dish were lysed in 1 ml of lysis buffer (20mM Hepes, pH 7.9, 150 mM 572 
NaCl, 1mM MgCl2, 1% NP40, 10 mM NaF, 0.2 mM NaVO4, 10 mM β-glycerol phosphate) with freshly 573 
added DTT (1 mM) and a proteinase inhibitor cocktail (Roche, Indianapolis, USA). The cells were 574 
incubated for 30 minutes on ice and sonicated with a Bioruptor Sonicator (Diagenode, Denville, USA). 575 
The extracts were cleared by centrifugation at 12,000×g for 15 min at 4 °C. Immunoprecipitations were 576 
performed at 4°C in lysis buffer in the presence of RNaseA (10µg/ml) using indicated antibody and 50 µl 577 
of 50% (V/V) slurry of Protein A agarose (Roche, Indianapolis, USA) or anti-Flag M2 agarose (Sigma, St. 578 
Louis, USA) for 4 hours. The precipitates were extensively washed and resuspended in 2×SDS-PAGE 579 
sample buffer directly. The immunopurified protein and cell lysates were resolved by 10% SDS-PAGE 580 
and transferred to PVDF membranes (Millipore, Billerica, USA) for western blot assays. The proteins 581 
were visualized by the Immobilon Western Chemiluminescent horseradish peroxidase substrate 582 
detection kit (Millipore). PRMT1-V2 specific antibody was reported (Baldwin et al., 2012). The other 583 
antibodies used were commercially available, including anti-Flag M2 Ab (#F1804, Sigma), RBM15 584 
monoclonal antibody (#66059-1-1g, Proteintech, Chicago), RBM15 polyclonal antibody (#: 10587-1-AP, 585 
Proteintech, Chicago), PRMT1 (#07404, Upstate Biotechnology), SF3B1 (#PA5-19679, Thermo 586 
Scientific), Ub (#U5397, Sigma) and GAPDH (#MA5-15738, Thermo Scientific, Waltham). 587 
Detection of in vivo Ubiquitylation  588 
HEK293T cells transfected with Flag-RBM15 and His-ubiquitin expression plasmids for 40 hours were 589 
treated with 10 µM MG132 for 6 hours before harvesting. Cells were lysed in buffer A (6 M guanidine-590 
HCl, 0.1 M Na2HPO4/NaH2PO4, pH 7.5, 10 mM imidazole) at 4°C for 15 minutes. The lysate was 591 
sonicated for 20 cycles in Bioruptor Sonicator. After cleaned by centrifugation at 12,000g for 30 minutes 592 
at 4°C, the supernatant was incubated with Ni2+-NTA beads (QIAGEN, Valencia, USA) for 3 hours at 593 
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room temperature. The beads were sequentially washed with buffer A, buffer B (1.5 M guanidine-HCl, 25 594 
mM Na2HPO4/NaH2PO4, 20 mM Tris-Cl [pH 6.8], 17.5 mM imidazole), and buffer C (25 mM Tris-Cl [pH 595 
6.8], 20 mM imidazole). The ubiquitin-conjugated proteins were boiled in 2×SDS-PAGE loading buffer 596 
containing 200 mM imidazole and subjected to immunoblot analysis.  597 
 Real-time PCR Assay 598 
Total RNA was prepared using RNeasy plus Kit (QIAGEN). cDNA was generated by the Verso cDNA 599 
synthesis Kit (Thermo Scientific) with random hexamer primers. Real-time PCR assays were performed 600 
with Absolute Blue qPCR SYBR green Mix (Thermo Scientific) or Taqman Universal Master Mix II 601 
(Applied Biosystems, for GATA1-FL and GATA1-S) on a ViiA 7 system (Applied Biosystems). Primers 602 
are listed in Supplementary file 2. GAPDH was used as an internal control for normalization. Relative 603 
expression level was calculated by ∆(∆ct) method and all results were expressed as mean values± 604 
standard errors from at least 3 independent experiments. 605 
GATA1 isoforms can be detected by regular PCR reactions with the primers: GATA1 Ex1 F : 606 
ATCACACTGAGCTTGCCACA, GATA1 Ex3 R: AGCTTGGGAGAGGAATAGGC in Figure 5H.  607 
 608 
Identification of protein methylation by mass spectrometry 609 
For identification of methylation sites of targeted proteins, samples were separated by 10% of SDS 610 
PAGE.  The gel band were excised from the gel, reduced with 10 mM DTT and alkylated with 55 mM 611 
iodoacetamide. Then in-gel digestion was carried out with the sequencing grade modified trypsin 612 
(Promega, Fitchburg, WI) in 50 mM ammonium bicarbonate at 37 C overnight. The peptides were 613 
extracted twice with 1% trifluoroacetic acid in 50% acetonitrile aqueous solution for 30 min. The 614 
extractions were then centrifuged in a speedvac to reduce the volume. 615 
 616 
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For LC-MS/MS analysis, the digested product was separated by a 60 min gradient elution at a flow rate 617 
0.30 µL/min using an UltiMate 3000 RSLCnano System (Thermo Scientific, USA) which was directly 618 
interfaced with a Thermo Q Exactive benchtop mass spectrometer. The analytical column was a home-619 
made fused silica capillary column (75 µm ID, 150 mm length; Upchurch, Oak Harbor, WA) packed with 620 
C-18 resin (300 Å, 5 µm, Varian, Lexington, MA). Mobile phase A consisted of 0.1% formic acid, and 621 
mobile phase B consisted of 100% acetonitrile and 0.1% formic acid. The mass spectrometer was 622 
operated in the data-dependent acquisition mode using the Xcalibur 2.2.0 software and there is a single 623 
full-scan mass spectrum in the Orbitrap (400-1800 m/z, 70,000 resolution) followed by 8 MS/MS scans 624 
under the higher energy collision dissociation (HCD). The MS/MS spectra from each LC-MS/MS run 625 
were searched against the selected database using an in-house Mascot or Proteome Discovery 626 
searching algorithm. 627 
Peptide pulldown assay  628 
The peptide pulldown method is published before (Vu et al., 2013). Briefly, two peptides (Biotin-629 
LLYRDRDRME2ADLYPDSDWV and Biotin-LLYRDRDRDLYPDSDWV) with or without methylation on 630 
R578 were synthesized. Biotin was added for binding to streptavidin beads. 200 μl of the whole cell 631 
extract (10mg/ml in H lysis buffer) prepared as mentioned in co-immunoprecipitation assays was used to 632 
incubate with peptides (at final concentration of 1 μM) overnight at 4°C. The beads were washed with 633 
wash buffer (300mM NaCl, 1mM DTT, 20mM Tris pH 7.4 and 0.1% NP40) five times. Protein bound to 634 
the beads were boiled in SDS sample buffer and resolved in 10% SDS PAGE.  635 
Survival analysis:  636 
RNA-seq data of 200 acute myeloid leukemia (AML) samples were downloaded from the Cancer 637 
Genome Atlas (TCGA). The PRMT1 expression levels were used for survival analysis using Kaplan 638 
Meier (K-M) curves and log-rank tests. Samples with available clinical outcomes (survival month, n=103) 639 
data were included in the analysis. Logarithm 2-based transformations of each gene were performed 640 
prior to any analysis. Significant association was determined at 5% type I error level. 641 
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Target CNOT4 by CRISPR 642 
 643 
Two guide RNAs were designed to target exon 2 of human CNOT4 at two different sites using the 644 
CRISPR design tool (Zhang’s lab) (Ran et al., 2013b). The distance between target sites is roughly 645 
100bp. Two gRNAs were cloned into pX330 vector, and transient transfected into 293T cells. Single cells 646 
were selected by serial dilution. Single cell colonies were screened for internal deletion by PCR using 2 647 
primers: F: TTCCCCTAAAATGTGTTATGATGA; R : CCAGTGCAGTGTTCTTTCCA. Guide RNA 648 
sequences: (1) CACCG GGATGTCATGTCCTCAGCGT; (2) CACCGGTGGATGCCAAAGTGTGCGT. 649 
Developing anti-peptide antibody against RBM15  650 
RBM15 N-terminal sequence (Acetyl-RTAGRDPVPRRSPRWRRAVPLC) was used to develop rabbit 651 
polyclonal antibody against RBM15 by GeneMed Synthesis Inc. (St. Antonio, Texas) for RNA 652 
immunoprecipitation assay. 653 
 654 
RNA immunoprecipitation assay 655 
Ten millions of MEG-01 cells grown at the exponential phase were cross-linked by 1% of formaldehyde 656 
in 37°C incubator for 10 minutes. Cells were washed twice with ice-cold PBS, lysed in H-lysis buffer 657 
(20mM HEPES pH7.9, 300mM NaCl, 1mM MgCl2, 1% NP40, NaF 10mM, 0.2mM NaVO4, 10mM β-658 
glycerol phosphate, 5% glycerol, 1mM DTT, 40 U/ml RNaseOUT, and proteinase inhibitors), and then 659 
sonicated by Bioruptor (Diagenode) to fragments with average sizes of 200bp (DNA) for 30 minutes at 660 
4oC. After the lysate was spun down, the supernatant was incubated with RBM15 antibody overnight at 661 
4oC. Beads were washed five times with stringent buffer (50mM Tris pH7.5, 1M NaCl, 1mM EDTA, 662 
0.1%SDS, 1% Na Deoxycholate, 1M Urea, and 1% NP40), and once with TE buffer (10mM Tris pH 7.9, 663 
1mM EDTA). Immunoprecipitated RNA were eluted by incubating with 150μl RIP elution buffer (50mM 664 
Tris-Cl pH 7.9, 5mM EDTA, 1% SDS, 200mM NaCl and 267 μg/ml of proteinase K) for 1h at 45°C. 665 
Genomic DNA was removed by DnaseI Turbo (Ambion). RNA was extracted by Trizol (Invitrogen) and 666 
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cDNA was synthesized with random priming  (Thermo Verso cDNA synthesis kit). The cDNA was 667 
analyzed by qRT-PCR.  668 
We did two biological replicates for RIP-seq experiments with anti-RBM15 antibody and normal IgG 669 
respectively. The RNA was converted into cDNA using SureSelect single strand RNA selection kit 670 
(Illumina) and sequenced with Illumina 2000 sequencer.  671 
 672 
Primary cell culture for megakaryocyte differentiation  673 
G-CSF mobilized peripheral human blood cells were used to purify CD34+ cells. These CD34+ cells were 674 
spinfected with lentiviruses and grown in basic cytokine mix (100ng/ml of SCF, 100ng/ml FLt3 ligand, 675 
50ng/ml of IL-6 and 20ng/ml of TPO) with IMDM medium plus 20% BIT (Stem cell Technology). For 676 
megakaryocyte differentiation, we cultured the CD34+ cells with 50ng/ml TPO and 2ng/ml of SCF. The 677 
maturation of MK cells was assessed for the percentage of CD41+CD42+ or CD61+CD42+ populations as 678 
well as the percentage of polyploidy with PI staining by FACS analysis.  679 
 680 
Computational analysis of RIP-seq data and RNA-seq data 681 
We first trimmed adaptor sequences and low quality bases from paired end RIP sequencing reads using 682 
Trimmomatic (Bolger et al., 2014). Processed reads were then mapped to hg19 genome with the STAR 683 
(Dobin et al., 2013) aligner. RIP reads from all samples were summarized into read coverage profiles on 684 
all chromosomes, and peaks were identified with a custom algorithm (Loeb et al., 2012) by convolving 685 
the read coverage signal with the second derivative of a Gaussian filter (bandwidth = 300). For each 686 
peak, we used DESeq (Anders and Huber, 2010) to test if there was significant difference in read counts 687 
within the peak region between RBM15 samples and control samples after correcting for library size 688 
differences. 1515 peaks with more reads in RBM15 samples and FDR < 5% were defined as significant 689 
RBM15 binding sites. Each peak was annotated with information including gene name and region (i.e. 690 
intron, 3’UTR, 5’UTR, CDS) according to the overlapping RefSeq transcript. 691 
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We did 100bp pair ends sequencing for the RNA samples. More than 100 million reads per sample were 692 
collected. All the reads were mapped to the human reference genome (GRCh37/hg19) using STAR with 693 
a Gene Transfer File (GTF version GRCh37.70). The mean insert sizes and the standard deviations 694 
were calculated using Picard-tools (v1.126) (http://broadinstitute.github.io/picard/). 695 
Differential exon usage was calculated by DEXSeq (Anders et al., 2012) and an even-based analysis 696 
using MISO (Katz et al., 2010) to measure the abundance of event types: skipped exon (SE), mixed exon 697 
usage (MXE), alternative first exon (AFE), alternative last exon (ALE), alternative 5’ or 3’ splicing sites 698 
(A5SS or A3SS) and tandom 3’UTR use (T3UTR). The Read Per Million (RPM) normalized BigWig files 699 
were generated using BEDTools (v2.17.0) and bedGraphToBigWig tool (v4). And all the downstream 700 
statistical analyses and generating plots were performed in R (v3.1.1) (http://www.r-project.org/). All the 701 
RNA-seq and RIP-seq data were deposited in NIH (GSE73893).  702 
 703 
In vitro ubiquitylation assay  704 
In vitro ubiquitination assay was performed essentially as described (Wang et al., 2004). Briefly, RBM15 705 
or RBM15 R578K with or without PRMT1-mediated methylation were incubated with HA-CNOT4 in 32.5 706 
μl reaction mixture containing 50 mM Tris (pH7.5), 5 mM MgCl2, 2 mM NaF, 2 mM ATP, 10 mM Okadaic 707 
acid, 0.6 M DTT, 0.1 mg E1, 0.2 mg UBCH5C and1 mg recombinant ubiquitin (Sigma). Reactions were 708 
carried out for 1 hour at 37°C before stopping with SDS sample loading buffer and resolving by 8% SDS-709 
PAGE. Ubiquitination was detected by Western blot with anti-Flag antibody. 710 
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Figure legends 735 
 736 
Figure 1. RBM15 is methylated by PRMT1 at R578 in mammalian cells. (A) Alignment of RBM15 737 
sequences among different species shows R578 within a conserved protein region. (B) RBM15-Flag and 738 
its mutant (R578K), affinity purified with anti-Flag antibody from transfected 293T cells, were detected by 739 
western blot (WB) with anti-monomethyl arginine antibody. (C) Flag-tagged RBM15 was affinity purified 740 
by Flag antibody for WB with two generic antibodies against mono-methyl arginine and dimethyl arginine 741 
respectively. The 293T cells overexpressing wild type RBM15-Flag protein with PRMT1 V2 (lane 2) and 742 
V1 (lane 3) respectively were treated with 20nM MG132 for 6 hours before harvesting. (D) The 743 
differences between N terminal sequences of PRMT1 V1 and V2 isoforms. (E) In vitro methylation 744 
assays. Affinity purified RBM15 protein was methylated by incubation with purified HA-PRMT1 and 0.15 745 
mM of S-adenosyl-methionine at 30°C for four hours. The methylated RBM15 was detected by anti-746 
dimethyl arginine antibody in WB. (F) RBM15 was immunoprecipitated with a mouse monoclonal anti-747 
RBM15 antibody from whole cell extract prepared from a MEG-01 stable cell line expressing inducible 748 
shRNA against PRMT1. Normal IgG was used as immunoprecipitation controls. The immunoprecipitated 749 
RBM15 was detected by WB with antibodies against mono-methyl arginine (mono-R100) and 750 
asymmetrical dimethyl arginine (D4H5) respectively. As controls, we did WB with anti-PRMT5 and anti-751 
PRMT4 antibodies. (G) Detection of methylated RBM15 in MEG-01 stable cell lines expressing Flag-752 
RBM15 and R578K mutant proteins respectively after a PRMT1 inhibitor (DB75) treatment for 24 h. 753 
RBM15 is affinity purified by anti-Flag antibody and detected by WB with mono-methyl arginine antibody 754 
and dimethyl arginine antibody.  755 
Figure 1-figure supplement 1. PRMT1 is overexpressed in AMKL leukemia and associated with short 756 
survival rate in AML. 757 
Figure 1-figure supplement 2. RBM15 is discovered as a PRMT1 substrate via BPPM. 758 
Figure 1-figure supplement 3. Mapping the methylation site for RBM15. 759 
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Figure 1-figure supplement 4. RBM15 methylation status is further confirmed by a methyl-RBM15 760 
antibody. 761 
Figure 2. PRMT1 V2 isoform destabilizes RBM15 via methylation. (A) WB for RBM15 in 293T cells 762 
overexpressing PRMT1 V1 and V2 respectively. PRMT1 V2 was detected by anti-V2 specific antibody 763 
(PRMT1 V2). PRMT1 V1 and V2 were detected by an antibody for all isoforms (labeled as PRMT1). (B) 764 
The level of the RBM15 protein as detected by WB in MEG-01 cells treated with methyltransferase 765 
inhibitors (Adox and MTA mix) or DB75. (C) RBM15 protein level was measured by WB in MEG-01 cells 766 
with two doxycycline-inducible shRNA against PRMT1 (on the left). In the middle and right sides are real 767 
time PCR results to show the mRNA levels of total amount of PRMT1, PRMT1 V2, and RBM15 in 768 
shPRMT1#1 stable MEG-01 cell line (middle) and in shPRMT1#2 stable MEG-01 cells (right). All data 769 
are presented as mean ± SD from three independent experiments. (D) RBM15 protein level was 770 
measured by WB in MEG-01 cells induced by doxycycline to express PRMT1 V2 isoform. On the right 771 
are the real-time PCR charts for PRMT1 V2 and RBM15 mRNA levels. Data are presented as mean ± 772 
SD from three independent experiments. (E) RBM15 protein level was accessed by WB in a MEG-01 773 
stable cell line expressing shRNA against V2. The names of antibodies are listed on right.  The pRS 774 
vector retrovirus infected MEG-01 cells were used as control. (F) WB with anti-Flag antibody to detect 775 
the protein levels of RBM15 wild type and R578K mutant proteins in 293T cells overexpressing PRMT1 776 
V2 and RBM15 proteins. (G) The half-life of the RBM15 proteins in MEG-01 cells, and stable cell lines 777 
overexpressing Flag tagged RBM15 and RBM15 R578K were assessed by WB respectively. 778 
Cyclohemixide were added to stop protein synthesis 30 minutes before harvesting cells as the 0 time 779 
point. The half-life curves were plotted by GraphPad Prism 6.  780 
 781 
Figure 3. The RBM15 is ubiquitylated in a methylation-dependent manner. (A) Western blots for the 782 
RBM15 protein from MEG-01 cells treated with the proteasome inhibitor MG132. (B) The ubiquitylated 783 
RBM15-Flag was detected by anti-Flag antibody. The poly-ubiquitylated RBM15 was purified with nickel 784 
beads under denaturing conditions (6M of guanidine-HCl) from 293T cells expressing RBM15-Flag and 785 
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poly-histidine-tagged ubiquitin. (C) The ubiquitylated RBM15 was measured by anti-ubiquitin antibody 786 
after affinity purified with Flag antibody from MG132 treated 293T cells expressing RBM15-Flag or 787 
R578K-Flag and ubiquitin. (D) IP-western blot for poly-ubiquitylated RBM15 in DB75 treated MEG-01 788 
cells. The endogenous RBM15 protein was immunoprecipitated by anti-RBM15 antibody and then blotted 789 
with anti-ubiquitin antibody and anti-RBM15 antibody. (E) The ubiquitylated RBM15 was detected by anti-790 
Ub antibody after RBM15-Flag as well as its mutant was affinity purified from 293T cells transfected with 791 
combinations of plasmids shown above the gel. CNOT4 was detected via its HA tag. (F) WB to detect 792 
RBM15 protein levels in two MEG-01 cell lines expressing two different shCNOT4 respectively. PRMT1 793 
inhibitor (DB75) was used to treat the cells expressing shCNOT4 RNAs. The efficiency of shCNOT4 794 
knockdown was checked by real-time PCR. (G) In vitro ubiquitylation assays with CNOT4 and RBM15. 795 
Purified PRMT1 was added to methylate RBM15 in vitro in lanes 5 and 6 first before incubating with 796 
CNOT4 for in vitro ubiquitylation assays. All components were affinity purified from 293T cells. The 797 
ubiquitylated RBM15-Flag was detected by WB with anti-Flag antibody. (H) CNOT4 from MEG-01 whole 798 
cell extract was pulled down with methylated and nonmethylated peptides of RBM15. CNOT4 was 799 
detected by WB with anti-CNOT4 antibody.   800 
Figure 3-figure supplement 1. Purified proteins used in vitro methylation and ubiquitylation assays. 801 
Figure 3-figure supplement 2. The efficiency of CNOT4 knockdowns. 802 
 803 
Figure 4. PRMT1 controls the protein level of RBM15 in megakaryocyte maturation. (A) WB to measure 804 
the protein levels in MEG-01 cells stimulated to maturation by PMA. The left panel (WB results) showed 805 
the protein levels by antibodies against GAPDH, RBM15, Methyl-RBM15, PRMT1 with a PRMT1 806 
antibody against all isoforms and PRMT1 V2 with specific V2 antibody during the course of maturation. 807 
The middle panel shows the quantitation of the protein bands in the western blots on the left normalized 808 
to GAPDH. The right panel showed the decrease of PRMT1 V2 by real time PCR during maturation with 809 
GAPDH mRNA as an internal control. Real-time PCR data were presented as means ± SD from three 810 
independent experiments. (B) Histograms of CD41+ cells on PMA treated MEG-01 cells overexpressing 811 
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RBM15 and RBM15R578K mutant proteins respectively on day 3. The percentage of CD41+ cells was 812 
calculated according to matched antibody isotype control. Three independent experiments were done 813 
with statistics shown on the left. P*** <0.001, P** <0.01. (C) FACS analysis of the polyploid status of 814 
PMA treated cells overexpressing RBM15 and R578K mutant proteins by PI staining. Vector: lentivirus 815 
vector. P*** <0.001. (D) The matured MK cells were measured by CD61+CD42+. Human adult CD34+ 816 
cells in pro-megakaryocyte differentiation medium were treated with DB75 for three days. Three 817 
independent experiments were done with P*< 0.05. (E) Human adult CD34+ cells were infected with 818 
lentivirus expressing PRMT1 V2 or lentivirus vector and grown in pro-MK differentiation medium for five 819 
days. Three independent experiments were done with P***<0.001. (F) Human adult CD34+ cells were 820 
infected with two lentiviruses expressing shRNAs against RBM15 and grown in pro-MK differentiation 821 
medium. Three biological replicates were used for P value. P** <0.01. (G) Human adult CD34+ cells were 822 
infected with lentiviruses expressing RBM15 or R578K proteins and grown in pro-MK differentiation 823 
medium for five days. Three independent experiments were done with P**<0.01. (H) Human adult CD34+ 824 
cells were infected with lentiviruses expressing RBM15 or R578K together with a lentivirus expressing 825 
PRMT1 V2 and grown in pro-MK differentiation medium. Three biological replicates were used for P 826 
value. P**<0.01.  827 
Figure 4-figure supplement 1. Relative expression levels of PRMT1 isoforms and RBM15 in different 828 
hematopoietic lineages derived from mouse and human. 829 
Figure 4-figure supplement 2. RBM15 protein level in MEG-01 cell lines expressing two shRNA 830 
constructs against RBM15 respectively by western blots.  831 
 832 
Figure 5. Analysis of RBM15 target genes. (A) Real-time PCR assays for detecting RNA associated with 833 
RBM15 in MEG-01 cells by RNA immunoprecipitation assays (RIP) with the RBM15 antibody. The levels 834 
of RBM15-associated mRNAs were calculated as mean ± SD from three independent experiments. (B) 835 
The distribution of RBM15 binding sites. All the RBM15 target genes were listed in Figure 5 -source file 836 
2. (C) Gene ontology (GO) pathway analysis (FDR<0.01) showed pathways associated with genes which 837 
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have RBM15 binding sites in introns. (D) GO pathway analysis (FDR <0.01) revealed pathways 838 
associated with genes containing RBM15 binding sites in 3’UTR regions. (E) Differential exon usage 839 
events detected by MISO program. T3UTR: tandem UTR. SE: skipped exon. RI: retention intron. MXE: 840 
mutually exclusive exon usage. ALE: alternative last exon. AFE: alternative first exon. A5SS: alternative 841 
5’ splicing sites. A3SS: alternative 3’ splicing sites. (F) The changes of percentage splice-in events in 842 
different splicing categories when RBM15 is knocked down. (G) MISO plot for skipping of GATA1 exon 2 843 
when RBM15 was knocked down. (H) Isoforms of GATA1fl and GATA1s were detected by PCR using 844 
RNA extracted from MEG-01 cells with or without RBM15 knockdown.  845 
Figure 5-figure supplement 1. RBM15 binding to pre-mRNA of genes known important for 846 
hematopoiesis. 847 
Figure 5-figure supplemental 2. The RBM15 binding profiles on the c-MPL (panel A) and RUNX1 848 
(panel B) pre-mRNAs. 849 
Figure 5-figure supplement 3. The mitochondria biogenesis is regulated by the PRMT1-RBM15 850 
pathway. 851 
Figure 5-figure supplement 4. Representative genes detected by MISO and DEXSeq in the RIP group.  852 
Figure 5-source file 1: Identification of RNAs associated with RBM15 by RNA immunoprecipitation 853 
assay with anti-RBM15 antibody. Genes related to MK differentiation are highlighted.  854 
Figure 5-source file 2: Analysis of gene expression profile changes with RNA-seq data from RBM15 855 
knockdown MEG-01 cells. Genes related to MK differentiation are highlighted. 856 
Figure 5-source file 3: Analysis of differential exon usage regulated by RBM15 with RNA-seq data from 857 
RBM15 knockdown MEG-01 cells. Genes related to MK differentiation are highlighted. 858 
Figure 6. Methylation of RBM15 controls alternative splicing of genes (RUNX1, GATA1 and c-MPL) 859 
important for megakaryocyte differentiation. (A) Alternative splicing of RUNX1, GATA1, c-MPL in MEG-860 
01 cells and MEG-01 derived stable cell lines overexpressing RBM15 and PRMT1 V2 or knocking down 861 
RBM15 and PRMT1 V2. The ratios of different isoforms were calculated from real-time PCR assays with 862 
isoform specific primers. At least three independent experiments were performed. P****: <0.01; P***: 863 
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<0.05; P**: <0.2 and P*: <0.3 as compared to their respective vector control groups. (B) Time course for 864 
alternative splicing of RUNX1, GATA1 and c-MPL in human adult CD34+ cells grown in pro-MK 865 
differentiation medium. Three independent experiments were used to calculate the standard deviation. 866 
(C) The alternative splicing of GATA1, RUNX1 and c-MPL was measured as ratio change in human adult 867 
CD34+ cells treated with DB75 overnight in basic cytokine mix. Three independent experiments were 868 
used to calculate the P values.  869 
Figure 6-figure supplement 1. Alternative splicing of GATA1 is regulated by PRMT1 in acute 870 
megakaryoblastic leukemia cell lines. 871 
Figure 6-figure supplement 2. Schematic diagram of MPL isoforms. 872 
Figure 6-figure supplement 3. Alternative splicing of c-MPL is measured as the ratios of different 873 
isoforms by real-time PCR assays. 874 
 875 
Figure 7. RBM15 directly recruits the intron binding splicing factor, SF3B1, for alternative RNA splicing. 876 
(A) The interaction between SF3B1 and RBM15 in the context of PRMT1-mediated methylation. RBM15-877 
Flag and RBM15 R578K-Flag expressed from two MEG-01 cell lines with or without DB75 treatment 878 
were immunoprecipitated with anti-Flag antibody for detecting interaction with SF3B1 by WB. (B) The 879 
endogenous SF3B1 was co-immunopreciptiated with anti-RBM15 antibody in MEG-01 cells expressing 880 
inducible shPRMT1. Normal mouse serum was used as a negative control. (C) RBM15 binding profile on 881 
GATA1 pre-mRNA based on RIP-seq data. The green peaks were the binding sites for RBM15 and the 882 
blue profile was the binding profile for normal IgG. Two biological replicates were used for bioinformatic 883 
analysis. The significant peaks were shaded with pink squares. (D) The regions where RBM15 (RIP with 884 
RBM15 antibody, left panel) and SF3B1 (RIP with SF3B1 antibody right panel) bound on GATA1 pre-885 
mRNA in MEG-01 cells (solid bar) and RBM15 knockdown MEG-01 cells (open bar) were mapped by 886 
real-time PCR assays. The locations of primers on the pre-mRNA of GATA1 were shown on the bottom. 887 
Three biological replicates were used to calculate the standard deviations. GAPDH intron 1 was used as 888 
negative controls for both antibodies. (E) The regions on c-MPL pre-mRNA, where RBM15 and SF3B1 889 
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bound in MEG-01 cell lines expressing shRBM15 (square line) or expressing pLKO vector (solid dot line), 890 
were assessed by RIP with RBM15 (left panel) and SF3B1 antibodies (right panel). The locations of 891 
primers on the pre-mRNA of c-MPL were shown on the bottom. Three biological replicates were used for 892 
standard deviations. (F) A model for RBM15-mediated regulation of alternative RNA splicing. RBM15 and 893 
SF3B1 cooperate to produce GATA1fl and low level of RBM15 leads to lower SF3B1 binding and 894 
skipping of the exon 2. PRMT1-mediated methylation of RBM15 controls the ubiquitylation of RBM15 by 895 
CNOT4, thus controls the balance between proliferation and differentiation in megakaryopoiesis. 896 
Figure 7-source file 1: Mass spectrometry analysis of RBM15-associated proteins.  897 
Figure 1-figure supplement 1. PRMT1 is overexpressed in AMKL leukemia and associated with short 898 
survival rate in AML.  (A) PRMT1 is overexpressed in AMKL leukemia compared to other types of AML. 899 
Microarray data set (GSE4119) (Bourquin et.al. 2006) was analyzed by NCBI GEO2R tool. Expression 900 
values were exported from NCBI GEO2R tool and then re-plotted by GraphPad PRISM 5 software. (B) 901 
PRMT1 high expression is correlated with low survival rate in acute myeloid leukemia.  902 
 903 
Figure 1-figure supplement 2. RBM15 is discovered as a PRMT1 substrate via BPPM.  (A) Schematic 904 
description of substrate identification with PRMT1 Y39FM48G and Pob-SAM using BPPM technology. 905 
(B) HEK293T cells were transfected with either empty vector or the PRMT1 Y39FM48G mutant, followed 906 
with treatment of Adox to induce hypomethylation. These cells were then lysed to release the PRMT1 907 
substrates as previously described and the cell lysates were treated with Pob-SAM cofactor. The 908 
terminal alkyne-modified substrates were conjugated with the cleavable azido-azo-biotin probe, followed 909 
by streptavidin enrichment, sodium dithionite elution and western blotting detection. (C) Western blotting 910 
analysis of the pull-down substrate of PRMT1. The eluted targets of PRMT1 were incubated with RBM15 911 
antibody. The pull-down sample from 293T cells transfected with PRMT1 Y39FM48G variant showed 912 
significantly higher level of RBM15 compared to the control group. Cell lysates without streptavidin 913 
enrichment were assessed by anti-RBM15 western blotting as loading control (Input panel).  914 
 915 
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Figure 1-figure supplement 3. Mapping the methylation site for RBM15. (A) Tandem Mass 916 
Spectrometry analysis for Flag-tagged RBM15 purified from 293T cells overexpressing RBM15-Flag. The 917 
arrow indicates the modified peptide. (B) Schematic diagram shows domains on RBM15. (C) Dot blot to 918 
test the antibody (Mono-R100 from Cell Signaling) recognizing monomethylated RBM15 peptide based 919 
on mass spectrometry analysis. Nitrocellulose membrane was spotted with peptides with no modification, 920 
with arginine mono-methylated or with arginine asymmetrically dimethylated. The peptide sequences 921 
were listed on the right side of the dot blot gel. (D) Dot blot to test the antibody (D4H5 from Cell 922 
Signaling) which recognizes asymmetrically dimethylated RBM15 peptide. Peptides were spotted in the 923 
same order as in panel C. (E) IP-Western blot for RBM15 protein in Meg-01 cell lines expressing Flag-924 
tagged RBM15 and Flag-tagged RBM15 R578K respectively. The anti-monomethyl arginine antibody 925 
was used for immunoprecipitation and the ectopically expressed RBM15 proteins were detected by Flag 926 
antibody. (F) IP-Western blotting assays for detecting methylated RBM15 and R3K mutant expressed in 927 
293T cells. RBM15-R3K stands for RBM15 protein with all the arginines in the LYRDRDRD sequence 928 
mutated to lysines. (G) The in vitro methylation reaction with peptide (LYRDRDRDLY) incubated with 929 
purified PRMT1. H4 peptide (20 mer) was used as a positive control. The methylated peptide was 930 
detected by the D4H5 dimethyl arginine antibody not by the mono-methyl antibody. 931 
 932 
Figure 1-figure supplement 4. RBM15 methylation status is further confirmed by a methyl-RBM15 933 
antibody. (A) Dot blot for the anti-methyl-RBM15 antibody. Synthesized RBM15 peptides with different 934 
methylation status on arginine 578 were spotted for blotting with the anti-methyl RBM15 antibody. (B to 935 
D) RBM15 methylation status was measured by anti-methyl-RBM15 antibody by western blotting.  (B) 936 
The whole cell extracts from 293T cells expressing PRMT1 were used for western blotting with the anti-937 
methyl RBM15 antibody. Empty vector was used as a control. (C) The whole cell lysates from 293T cells 938 
expressing wild type (WT) RBM15 or R578K mutant were used for western blotting. (D) A stable MEG-01 939 
cell line expressing doxycycline (Dox)-inducible shPRMT1 was used to knock down PRMT1. The 940 
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expression of methyl-RBM15 was measured by western blotting with anti-methyl RBM15 antibody, 941 
RBM15 antibody, PRMT1 antibody and GAPDH antibody respectively.  942 
 943 
Figure 3-figure supplement 1. Purified proteins used in vitro methylation and ubiquitylation assays. (A) 944 
The Flag tagged RBM15 protein was affinity purified by anti-Flag antibody from 293T cells 945 
overexpressing FLAG RBM15 protein as shown by Coomassie staining of 10% SDS-PAGE. (B) Affinity 946 
purified HA-CNOT4 and HA-PRMT1 proteins were shown by silver staining. Both proteins were produced 947 
in 293T cells transfected with pCDNA3-HA-PRMT1 and pCDNA3-HA-CNOT4 respectively. Anti-HA 948 
antibody (12Ca5) column was used to purify these proteins. Proteins were eluted by 0.5mg/ml of HA 949 
peptide (Sigma) in PBS.  950 
 951 
Figure 3-figure supplement 2. The efficiency of CNOT4 knockdowns. (A) Real-time PCR assays for 952 
CNOT4 in MEG-01 cells expressing shCNOT4. (B) Western blots to show the knockdown efficiencies of 953 
two shRBM15 constructs in MEG-01 cells. (C) Using CRISPR to knockdown CNOT4 in 293T cells (A5 is 954 
a 293T cell line with only one wild type allele of CNOT4) as shown by real-time PCR on the left and by 955 
western blot on the right.  RBM15 protein level goes up in CNOT4+/- cells by western blot assays.  956 
 957 
Figure 4-figure supplement 1. Relative expression levels of PRMT1 isoforms and RBM15 in different 958 
hematopoietic lineages derived from mouse and human. (A-C) The relative expression levels of total 959 
PRMT1 (including V1 and V2) (A), PRMT1 V2 (B) and RBM15 (C) in different mouse lineages were 960 
measured by real-time PCR. The expression level is normalized to GAPDH, then normalized to the level 961 
in long-term hematopoietic stem cells (LT-HSC). (D) The surface markers we used to sort mouse 962 
lineages. (E) The expression level of PRMT1 in different human hematopoietic lineages. (F) The 963 
expression level of RBM15 in different human hematopoietic lineages based on database from 964 
HemaExplorer. (G) The abbreviations for the different human hematopoietic lineages used in panels (E) 965 
and (F).  966 
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 967 
Figure 4-figure supplement 2. RBM15 protein levels in MEG-01 cell lines expressing two shRNA 968 
constructs against RBM15 respectively by western blots. 969 
 970 
Figure 5-figure supplement 1. RBM15 binding to pre-mRNA of genes known important for 971 
hematopoiesis. (A) RBM15 binding peaks on pre-mRNA of CDC42. (B) RBM15 binding sites on pre-972 
mRNA of macroH2A (H2AFZ). (C) RBM15 binding on pre-mRNA of TAL1. (D) RBM15 binding peaks on 973 
pre-mRNA of LEF1.  974 
 975 
Figure 5-figure supplement 2. The RBM15 binding profiles on the c-MPL (A) and RUNX1 (B) pre-976 
mRNAs. The red bar is calculated as significant peaks in bioinformatics analysis.  977 
 978 
Figure 5-figure supplement 3. The mitochondria biogenesis is regulated by the PRMT1-RBM15 979 
pathway. The mitotracker (MitoTracker deep red FM, Invitrogen) was used to stain active mitochondria in 980 
MEG-01 stable cell lines infected with lentivirus vector, lentivirus expressing shRBM15, and lentivirus 981 
overexpressing PRMT1 V1 and V2 respectively. The cell nuclei were stained with Hoechst.   982 
 983 
Figure 5-figure supplement 4. Representative genes detected by MISO and DEXSeq in the genes 984 
detected by RIP. In the MISO diagram, the red graph is for MEG-01 cells, and the orange diagrams are 985 
for two MEG-01 cell lines expressing two shRBM15 RNAs respectively. (A) TAL1 (aka SCL) skips exon 2 986 
and 3 as detected by DEXSeq and use alternative short 3’UTR after RBM15 was knocked down. TAL1 987 
has the exon 2 (1:47691115-47691561) skipped in RBM15 knockdown cells, which losses protein coding 988 
ability for transcript (bottom panel). (B) MacroH2A (H2AFZ) retains intron (4:100870543-100870820) 989 
when RBM15 protein level is reduced. (C) RUNX1 has multiple exon usage alteration events as 990 
40 
demonstrated by DEXSeq on the top. The E017 marks the change for generating RUNX1a (E7a is 991 
included) when RBM15 is knocked down. The bottom is MISO analysis showing that Exon 6 is skipped to 992 
generate a RUNX1 protein without the transcriptional repression region. This isoform was reported 993 
(Komeno et.al 2014). (D) CDC42 skips the exon 2a (1:22400587-22400712) or exon 2b (1:22400647-994 
22400712). Although the open reading frame is still intact with the skipping events, the change of 5’UTR 995 
might cause changing in efficiency of protein translation. 996 
Figure 6-figure supplement 1. Alternative splicing of GATA1 is regulated by PRMT1 in acute 997 
megakaryoblastic leukemia cell lines. P value was calculated from three independent repeats. ****P < 998 
0.01, *** P < 0.05.  999 
 1000 
Figure 6-figure supplement 2. Schematic diagram of MPL isoforms. (A) A new isoform of MPL (c-MPL-1001 
exon9-) (Genebank No. KF964490) was detected in MEG-01 cells. We synthesized cDNA from Meg-01 1002 
cells using Verso cDNA synthesis kit (Thermo Scientific) and performed regular PCR with primers as 1003 
reported (Li et al., 2000). Direct ligation of exon 8 with exon 10 generates a truncated MPL protein as 1004 
shown below. (B) Schematic diagram of c-MPL isoforms generated by alternative splicing. 1005 
 1006 
Figure 6-figure supplement 3. Alternative splicing of c-MPL is measured as the ratios of different 1007 
isoforms by real-time PCR assays. The data are the averages from three independent experiments with 1008 
SD. (A) the ratio between c-MPL72minus-exon9/c-Mpl-exon9+. (B) the ratio between c-MPL-tr/c-MPL-1009 
exon 9+. The c-MPL-tr stands for c-MPL isoform without exon 9 and exon 10. We also observed that the 1010 
ratio of the c-MPL isoform with 72bp missing in the exon 9 (i.e. c-MPL-72minus-exon9+) to c-MPL-exon 1011 
9+ mRNA is similarly changed like the ratio of c-MPL-exon 9-/c-MPL-exon 9+ mRNA upon 1012 
overexpression or knock-down of RBM15 or of PRMT1. We discovered that the ratio of c-MPL-tr (which 1013 
misses both exon 9 and exon 10) to c-MPL-exon9+ was changed likewise when the RBM15 level is 1014 
changed as shown in Figure 6. 1015 
41 
Supplementary file 1: The real-time PCR primers for human genes.  1016 
Supplementary file 2: shRNA sequences for knocking down CNOT4 and RBM15 genes in human cells.  1017 
  1018 
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Figure 1. RBM15 is methylated by PRMT1 at R578 in mammalian cells. 
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Figure 2. PRMT1 V2 isoform destabilizes RBM15 via methylation. 
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Figure 4. PRMT1 controls the protein level of RBM15 in megakaryocyte maturation.
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Figure 6. Methylation of RBM15 controls alternative splicing of genes (RUNX1, GATA1 and c-MPL) important for megakaryocyte 
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